Benchmarking female breast cancer survival in africa, Central and South america, and asia (SURVCAN-3).

IF 7.7 1区 医学 Q1 ONCOLOGY
Mariam Zahwe, Ariana Znaor, Aude Bardot, Shalaka Joshi, Kyu-Won Jung, Reza Malekzadeh, Maria Paula Curado, Gholamreza Roshandel, Maria Cristina Diumenjo, Armando Cortés, Rama Ranganathan, Patumrat Sripan, Daniel Jurado-Fajardo, Andrea Falaschi, Imjai Chitapanarux, Isabelle Soerjomataram
{"title":"Benchmarking female breast cancer survival in africa, Central and South america, and asia (SURVCAN-3).","authors":"Mariam Zahwe, Ariana Znaor, Aude Bardot, Shalaka Joshi, Kyu-Won Jung, Reza Malekzadeh, Maria Paula Curado, Gholamreza Roshandel, Maria Cristina Diumenjo, Armando Cortés, Rama Ranganathan, Patumrat Sripan, Daniel Jurado-Fajardo, Andrea Falaschi, Imjai Chitapanarux, Isabelle Soerjomataram","doi":"10.1093/jnci/djag294","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In limited-resource settings with high cancer mortality, conditional survival which is the probability of surviving given on survival after a certain period of time since diagnosis, can provide a patient-centred and clinically relevant prognosis indicator. We aimed to benchmark breast cancer prognosis using conditional survival estimates in Africa, Central and South America, and Asia.</p><p><strong>Methods: </strong>We included data for 197,766 females with breast cancer diagnosed in 2008-2012, from 53 population-based cancer registries with at least 3 years of follow-up across 22 countries. We estimated 3-year age-standardised net survival at diagnosis and 1-year post-diagnosis using period approach.</p><p><strong>Results: </strong>In all countries, 3-year survival estimates improved for females with breast cancer who had survived 1 year as compared to the 3-year survival estimates at diagnosis. Countries with poorer initial survival showed the largest increases in conditional survival at 3 years with the highest improvement seen in Zimbabwe (68% vs. 57%), Mauritius (90% vs. 83%), India (80% vs. 74%), and Malaysia (83% vs. 77%, conditional and at diagnosis survival, respectively). Improvement in survival was mainly found among females ≥70 years. Inequalities in survival across countries persisted, whereas 6 out of 10 countries of the Americas and 4 out of 8 Asian countries had conditional survival >90%, this was observed only in 1 out of 4 African countries.</p><p><strong>Conclusion: </strong>Our results highlight the importance of early care on improving breast cancer survival over time and serve as a resource for physicians and patients who are seeking an updated indicator of breast cancer prognosis.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2026-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JNCI Journal of the National Cancer Institute","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jnci/djag294","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In limited-resource settings with high cancer mortality, conditional survival which is the probability of surviving given on survival after a certain period of time since diagnosis, can provide a patient-centred and clinically relevant prognosis indicator. We aimed to benchmark breast cancer prognosis using conditional survival estimates in Africa, Central and South America, and Asia.

Methods: We included data for 197,766 females with breast cancer diagnosed in 2008-2012, from 53 population-based cancer registries with at least 3 years of follow-up across 22 countries. We estimated 3-year age-standardised net survival at diagnosis and 1-year post-diagnosis using period approach.

Results: In all countries, 3-year survival estimates improved for females with breast cancer who had survived 1 year as compared to the 3-year survival estimates at diagnosis. Countries with poorer initial survival showed the largest increases in conditional survival at 3 years with the highest improvement seen in Zimbabwe (68% vs. 57%), Mauritius (90% vs. 83%), India (80% vs. 74%), and Malaysia (83% vs. 77%, conditional and at diagnosis survival, respectively). Improvement in survival was mainly found among females ≥70 years. Inequalities in survival across countries persisted, whereas 6 out of 10 countries of the Americas and 4 out of 8 Asian countries had conditional survival >90%, this was observed only in 1 out of 4 African countries.

Conclusion: Our results highlight the importance of early care on improving breast cancer survival over time and serve as a resource for physicians and patients who are seeking an updated indicator of breast cancer prognosis.

非洲、中南美洲和亚洲女性乳腺癌生存基准(SURVCAN-3)。
背景:在资源有限且癌症死亡率高的环境中,有条件生存是指自诊断后一定时间内存活的概率,可以提供以患者为中心和临床相关的预后指标。我们的目的是利用非洲、中南美洲和亚洲的条件生存估计来确定乳腺癌预后的基准。方法:我们纳入了来自22个国家的53个基于人群的癌症登记处的197,766名2008-2012年诊断为乳腺癌的女性的数据,随访时间至少为3年。我们使用分期法估计诊断时3年年龄标准化净生存率和诊断后1年净生存率。结果:在所有国家,与诊断时的3年生存率相比,存活1年的女性乳腺癌患者的3年生存率都有所提高。初始生存期较差的国家在3年有条件生存方面的增幅最大,其中津巴布韦(68%对57%)、毛里求斯(90%对83%)、印度(80%对74%)和马来西亚(分别为83%对77%,条件生存和诊断生存)的增幅最大。生存率的改善主要见于≥70岁的女性。各国之间的生存不平等仍然存在,10个美洲国家中有6个国家和8个亚洲国家中有4个国家的条件生存率达到90%以上,而只有1 / 4的非洲国家观察到这种情况。结论:我们的研究结果强调了早期护理对提高乳腺癌生存率的重要性,并为寻求乳腺癌预后最新指标的医生和患者提供了资源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
17.00
自引率
2.90%
发文量
203
审稿时长
4-8 weeks
期刊介绍: The Journal of the National Cancer Institute is a reputable publication that undergoes a peer-review process. It is available in both print (ISSN: 0027-8874) and online (ISSN: 1460-2105) formats, with 12 issues released annually. The journal's primary aim is to disseminate innovative and important discoveries in the field of cancer research, with specific emphasis on clinical, epidemiologic, behavioral, and health outcomes studies. Authors are encouraged to submit reviews, minireviews, and commentaries. The journal ensures that submitted manuscripts undergo a rigorous and expedited review to publish scientifically and medically significant findings in a timely manner.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书